封面
市場調查報告書
商品編碼
1452446

血糖儀市場-按產品(自我監測血糖儀、連續血糖監測儀[穿戴式式、非穿戴式式])、應用(1 型、2 型和妊娠糖尿病)、配銷通路(醫院、零售、在線)-全球預測, 2024-2032

Glucometer Market - By Product (Self-monitoring Blood Glucose Meter, Continuous Glucose Monitor [Wearable, Non-wearable]), Application (Type 1, Type 2, & Gestational Diabetes), Distribution Channel (Hospital, Retail, Online)-Global Forecast, 2024-2032

出版日期: | 出版商: Global Market Insights Inc. | 英文 223 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在糖尿病管理領域持續研發活動的推動下,2024 年至 2032 年全球血糖儀市場規模將達到 12.8% 的CAGR。隨著研究人員開發創新技術並提高血糖儀的準確性和效率,醫療保健提供者和糖尿病患者正在尋求先進的解決方案。例如,2024 年 3 月,印度理工學院曼迪分校的研究人員推出了突破性的設備,無需血液樣本即可檢測糖尿病。該設備被稱為非侵入式血糖儀,透過分析氣球中的呼吸樣本來發揮作用,為傳統方法提供無痛且有效的替代方案。

隨著對個人化醫療保健和主動疾病管理的日益重視,對具有先進功能的血糖儀的需求將繼續成長,以塑造糖尿病護理的模式。持續血糖監測、無線連接和智慧型手機整合等增強功能的持續努力也將推動市場成長。

整個血糖儀產業分為產品類型、應用、配銷通路和地區。

從產品類型來看,自我監測血糖儀細分市場的市場佔有率將顯著發展,2024年至2032年的CAGR將達到15%。這些設備使糖尿病患者能夠在家中或在家中方便、準確地監測自己的血糖水平。在旅途中。隨著全球糖尿病盛行率的不斷上升,對有效的自我管理工具的需求日益成長。自我監測血糖儀可以讓使用者即時了解自己的血糖水平,以便主動管理自己的病情。隨著人們優先考慮主動健康監測,自我監測血糖儀的需求將持續穩定成長。

根據應用情況,2024年至2032年,1型糖尿病領域的血糖儀產業收入複合CAGR將達到12.4%。由於第1型糖尿病需要定期監測血糖水平以有效管理胰島素劑量,因此血糖儀在日常管理中發揮著至關重要的作用例行公事。這些設備為使用者提供有關血糖水平的即時回饋,從而能夠及時採取干涉措施以保持最佳健康狀況。隨著全球 1 型糖尿病盛行率不斷上升,針對此類患者量身定做的準確、可靠的血糖儀的需求將進一步增加。

亞太地區血糖儀市場從2024年到2032年將呈現13.5%的CAGR。隨著糖尿病盛行率的不斷上升以及人們對主動醫療保健管理的日益關注,該地區對血糖儀的需求不斷增加,以便個人能夠方便地監測血糖水平並有效地進行疾病管理。醫療保健基礎設施和意識的改善進一步推動了針對亞太地區人口多樣化需求的血糖儀的需求。例如,2023 年10 月,印度孟買州政府決定允許1-12 年級患有1 型糖尿病的學生在教室和考場食用零食和藥物,並配備血糖儀,這一決定受到了學校、家長和學生的熱烈歡迎。和非政府組織。

目錄

第 1 章:方法與範圍

第 2 章:執行摘要

第 3 章:產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 全球糖尿病盛行率上升
      • 技術進步
      • 全球對自我監控設備的需求不斷成長
      • 政府為提高人們的意識而採取的舉措
    • 產業陷阱與挑戰
      • 先進設備及配件成本高
      • 缺乏報銷和嚴格的規定
  • 成長潛力分析
  • 技術景觀
  • 波特的分析
  • PESTEL分析

第 4 章:競爭格局

  • 介紹
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略展望矩陣

第 5 章:市場估計與預測:按產品類型,2018 年 - 2032 年

  • 主要趨勢
  • 自我監測血糖儀
  • 連續血糖監測儀
    • 穿戴式
    • 不穿戴式

第 6 章:市場估計與預測:按應用,2018 - 2032

  • 主要趨勢
  • 1 型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

第 7 章:市場估計與預測:按配銷通路,2018 年 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網上銷售
  • 糖尿病診所和中心

第 8 章:市場估計與預測:按地區分類,2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 波蘭
    • 瑞士
    • 瑞典
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 印尼
    • 泰國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 科威特
    • 阿拉伯聯合大公國
    • 土耳其
    • 埃及
    • 以色列
    • 卡達
    • 中東和非洲其他地區

第 9 章:公司簡介

  • Abbott Laboratories
  • AgaMatrix
  • All Medicus Co., Ltd.
  • Ascensia Diabetes Care Holdings AG
  • Arkray, Inc.
  • B. Braun Melsungen AG
  • Bionime Corporation
  • DarioHealth Corporation
  • Dexcom, Inc.
  • Essenlife Bioscience, Inc.
  • F. Hoffmann-La Roche Ltd.
  • LifeScan Inc.
  • Medtronic plc
  • Nova Biomedical, Inc.
  • Sinocare Inc.
簡介目錄
Product Code: 8010

Global Glucometer Market size will witness 12.8% CAGR between 2024 and 2032 propelled by the ongoing R&D activities in the field of diabetes management. As researchers develop innovative technologies and improve the accuracy and efficiency of glucometers, healthcare providers and individuals with diabetes are seeking advanced solutions. For instance, in March 2024, researchers at IIT Mandi introduced a groundbreaking device capable of detecting diabetes without the necessity of blood samples. Termed as a non-invasive glucometer, this device functions by analyzing breath samples contained in a balloon for providing a painless and effective alternative to conventional methods.

With a growing emphasis on personalized healthcare and proactive disease management, the demand for glucometers with advanced capabilities will continue to rise for shaping the landscape of diabetes care. Rising efforts towards enhanced features, such as continuous glucose monitoring, wireless connectivity, and smartphone integration will also drive the market growth.

The overall glucometer industry is classified into product type, application, distribution channel and region.

In terms of product type, the market share from the self-monitoring blood glucose meters segment will undergo significant development, depicting 15% CAGR from 2024 to 2032. These devices empower individuals with diabetes to monitor their blood glucose levels conveniently and accurately at home or on the go. With the increasing prevalence of diabetes worldwide, there is a growing need for effective self-management tools. Self-monitoring blood glucose meters offer users real-time insights into their glucose levels for facilitating proactive management of their condition. With individuals prioritizing proactive health monitoring, the demand for self-monitoring blood glucose meters will continue to grow steadily.

Based on application, the glucometer industry revenue from the type 1 diabetes segment will register a 12.4% CAGR from 2024 to 2032. As type 1 diabetes requires regular monitoring of blood glucose levels to manage insulin dosages effectively, glucometers play a crucial role in daily management routines. These devices provide users with real-time feedback on their glucose levels, enabling timely interventions to maintain optimal health. With the rising prevalence of type 1 diabetes globally, the demand for accurate and reliable glucometers tailored to the needs of individuals with this condition will further increase.

Asia pacific glucometer market will showcase a 13.5% CAGR from 2024 to 2032. With a growing prevalence of diabetes and an increasing focus on proactive healthcare management, there is a heightened demand for glucometers in the region to enable individuals to monitor their blood glucose levels conveniently and effectively for disease management. The improving healthcare infrastructure and awareness is further driving the demand for glucometers tailored to the diverse needs of the Asia Pacific population. For instance, in October 2023, the state governments of Mumbai (India) decision to permit students in Class 1-12 with Type-1 diabetes to consume snacks and medication and a glucometer in classrooms and examination halls was warmly received by schools, parents, and NGOs.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of diabetes worldwide
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Rising demand for self-monitoring devices globally
      • 3.2.1.4 Government initiatives for increasing awareness among people
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of advanced devices and accessories
      • 3.2.2.2 Lack of reimbursement and stringent regulations
  • 3.3 Growth potential analysis
  • 3.4 Technology landscape
  • 3.5 Porter's analysis
    • 3.5.1 Supplier power
    • 3.5.2 Buyer power
    • 3.5.3 Threat of new entrants
    • 3.5.4 Threat of substitutes
    • 3.5.5 Industry rivalry
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Self-monitoring blood glucose meters
  • 5.3 Continuous glucose monitors
    • 5.3.1 Wearable
    • 5.3.2 Non - wearable

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Type 1 diabetes
  • 6.3 Type 2 diabetes
  • 6.4 Gestational diabetes

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospital pharmacies
  • 7.3 Retail pharmacies
  • 7.4 Online sales
  • 7.5 Diabetes clinics & centers

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Poland
    • 8.3.7 Switzerland
    • 8.3.8 Sweden
    • 8.3.9 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Indonesia
    • 8.4.7 Thailand
    • 8.4.8 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Colombia
    • 8.5.5 Chile
    • 8.5.6 Peru
    • 8.5.7 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 Kuwait
    • 8.6.4 UAE
    • 8.6.5 Turkey
    • 8.6.6 Egypt
    • 8.6.7 Israel
    • 8.6.8 Qatar
    • 8.6.9 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 AgaMatrix
  • 9.3 All Medicus Co., Ltd.
  • 9.4 Ascensia Diabetes Care Holdings AG
  • 9.5 Arkray, Inc.
  • 9.6 B. Braun Melsungen AG
  • 9.7 Bionime Corporation
  • 9.8 DarioHealth Corporation
  • 9.9 Dexcom, Inc.
  • 9.10 Essenlife Bioscience, Inc.
  • 9.11 F. Hoffmann-La Roche Ltd.
  • 9.12 LifeScan Inc.
  • 9.13 Medtronic plc
  • 9.14 Nova Biomedical, Inc.
  • 9.15 Sinocare Inc.